• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to new ergol-8-ene and ergoline derivatives of the general formula /I/ <IMAGE> /I/ wherein x y stands for -CH=C= or -CH2-CH= group, R stands for hydrogen atom or methyl group, R1 stands for hydrogen or halogen atom, R2 stands for lower alkylsulfonyloxy group, phenylsulfonyloxy group optionally substituted with a lower alkyl group, or azido group, R3 stands for lower alkylsulfonyloxy group or phenylsulfonyloxy group optionally substituted with a lower alkyl group, and acid addition salts thereof. These compounds can be prepared from compounds of the general formula II <IMAGE> /II/ wherein x y and R are as defined above, by reacting at least two equivalents of a lower alkylsulfonic acid chloride or phenylsulfonic acid chloride substituted with lower alkyl group. The resulting compound can be reacted with an alkali metal azide, and, if desired, the compound obtained is treated with a halogenating agent to form the 2-halogenide derivative, and, if desired, any resulting compound of general formula I is treated with an acid to form a therapeutically acceptable acid addition salt, or the free base is liberated from a salt. The compounds of general formula I possess valuable antiserotonine, antidepressant, dopamine receptor stimulant and hypotensive effects.
    公开号:SU1072806A3
    申请号:SU823394304
    申请日:1982-02-23
    公开日:1984-02-07
    发明作者:Маго Эржебет；Толди Лайош；Борши Йожеф；Тардош Ласло；Кирай Илдико；Ронаи Андраш
    申请人:Рихтер Гедеон Ведьесети Дьяр Рт (Инопредприятие)；
    IPC主号:
    专利说明:

    This invention relates to a process for the preparation of new ergoline alkaloid derivatives, namely ergol-8-ene or ergoline of general formula I
    R2 H2-1 -CH2-CH2-Kz
    Y-SL,
    Y
    - - / I
    where ES is CE-S or -CH-CH-;
    R is hydrogen or methyl; Ri is hydrogen or bromine; Na-Ci, -C alkylsulfonyl, or their salts, possess valuable pharmacological properties.
    The known compounds are: b-methyl-8) 3 (acetylaminomethyl) -ergoline, which exhibits oxytocin action; 1,6-dimethyl-8) 5- {benzyloxycarbonyl-aminomethyl) -ergoline, which has anti-toxic effect; 1-methyl-10o methoxydihydrolsergol-5-bromo-nikotktsat. reducing blood pressure of HA J.
    A known method for the preparation of 6-methyl-9-ergolen-8-acetic acid azide by the reaction of b-methyl-9-ergolen-8-acetic acid in a mixture of organic solvents with sodium azide upon teltrature from G23,
    There is also known a method for producing 2-bromo-substituted ergolium derivatives by brominating the corresponding ergoline derivative with n-bromosuccinimide in anhydrous dioxane at a temperature from room temperature to C3.
    The purpose of the invention is to obtain new synthetic derivatives of ergoline alkaloids.
    This goal is achieved in the manner in which the compound of the general formula
    2 CHa-lf-CHj-Clfj-R,
    j N-CH,
    where is x
    as indicated, R is hydrogen; H —C —C— —alkylsulfonyl,
     Group,
    is reacted with an alkali metal azide and, if necessary, brominated in position 2 with N-bromosuccinimide and the resulting target products are isolated in free form or in the form of salts.
    Example. Acidic maleic acid 6-methyl-8- {N-methanesulfonyl, N-azidoethyl) -aminomethyl-ergol8-ene.
    4.43 g of b-methyl-8 {N-methanesulfonyl, N-methanesulfonyloxy-ethyl) 5-aminomethyl-ergol-8-ene is dissolved with stirring in a mixture of 70 ml of methyl cellosolve and 7 ml of water. The resulting solution was mixed with 2.34 g of sodium azide and the mixture was boiled under reflux for 2 hours. The progress of the reaction is monitored by thin layer chromatography. At the end of the reaction, the solution was evaporated in vacuo and the residue was partitioned between 150 ml of water and 300 ml of chloroform. After shaking in a separatory funnel, the organic phase is separated, and additional 4 times from the aqueous phase are extracted with chloroform in 100 ml portions. The organic fractions are combined, dried, filtered and evaporated in vacuo. The crude product is dissolved in the solvent used as eluent and introduced into the column filled with
    5 60 g silica gel. The elution is carried out using a mixture of chloroform, water and ethanol, taken in a ratio of 100: 0.75: 20. The fractions with R 0.85 are combined and evaporated in vacuo. By treating the residue with an alcohol solution of maleic acid, salt is obtained. As a result, 4.23 g (82% of the theoretical yield) of acidic maleic acid 6-me5 f (N-methanesulfonyl, N-azidoethyl} -aminometi4-ergol-8-ena. Mp. 158-160C, fotj | 39 (with 0.5, 50% ethyl alcohol).
    Example2. Acidic maleic acid 2-bromo-b-methyl-8 - ((N-methane, sulfonyl, N-azidoethyl) -aminomethyl, J. Ergol-8-ene. I
    4.0 g of the free base of the product obtained by the method in accordance with Example 1 is dissolved with stirring at room temperature in 140 ml of anhydrous, free of hydrogen peroxide dioxane, and the resulting solution is mixed for 30 minutes with a solution of 1.8 g
    0 N-bromosuccinimide in 10 ml of dioxane. The reaction mixture is stirred at this temperature for 3 hours. The progress of the reaction is monitored by thin layer chromatography as described.
    5 in example 1 method. Chromatogram is developed using iodine vapor. At the end of the reaction, the reaction mixture is diluted with 210 ml of water, shaken in a separating funnel with 500 ml of chloroform, the pH of the aqueous phase is adjusted to 8 with ammonia, both the phases are then mixed again by shaking and finally the organic phase is separated. yut. From the aqueous phase with a pH of 8, 100 ml were extracted four times with chloroform. The organic phases are combined, dried over sodium sulfate, filtered and evaporated under vacuum. The crude product is dissolved in eluent and introduced into a column filled with 60 g of silica gel. The elution was carried out with chloroform containing 2 ethanol. The purity of the product obtained is controlled by thin layer chromatography. The eluent used for column chromatography is used as the mobile phase. Fractions with an Rt of 0.45 evaporation under vacuum, After removing the precipitate after evaporation with an alcoholic solution of maleic acid, salt is obtained. As a result, 3.76 g (63% of the theoretical yield) of the acid maleic acid 2-bromo-6-methyl-8 (N-methanesulfonyl, H-azidoethyl) aminomethyl-1-ergol-8-ene are obtained. T.: pl. 161, Toi, 6, base (c 0.1, pyridine)., Example 3. Tetrate 1,6-dimethyl-8- (N-methanesulfonyl, N-azidoethyl) -aminomethyl-ergol-8-ene . The same operations as in Example 1 are carried out. However, 4.6 g of 1,6-dimethyl-8-E (N-methanesulfonyl, N-methanesulfonyloxyethyl) aminomethyl 3-Ergol is used as the starting compound. The ene and the resulting base are treated with tartaric acid methanol solution. As a result, 3.3 g (59% of the theoretical yield) of 1,6-dimethyl-8 {(L-methanesulfonyl, N-azidoethyl) aminomethyl 1-ergol-8-ene tartrate are obtained. M.P., 168-170 ° C, roQ | --80, (c 0, 1, pyridine Example 4. 4. Tetrate 2-bromo-1,6 dimethyl-8- (N-methanesulfonyl, N- azidoethyl-aminomethyl-ergol-8-ene. The process is carried out as in Example 2, with the difference that 4, 14 g of 1,6-dimethyl-8- (N-methane sulfonyl, N-azidoethyl) -aminomethyl ergol-8-ene and the resulting base is treated with a methanol solution of tartaric acid. The result is 4.37 g of tartrate 2-bromo 1,6-dimethyl-8- (N-methanesulfonyl, N-azidoethyl) - aminomethyl ergol-8-ene, which corresponds to 68% of the theoretical yield.T.Pl. 111-113 s, foij |, r, -93 , (, l, pyridine), Pr ime r 5. Sour maleic acid 6-methyl-8 - (((N-methanesulfonyl, N-azidoethyl) -G # 1 sinomej-ergoline; the process is carried out as in Example 1 , with the difference that 4.55 g of 6-methyl-8- (N-MeTat-sulfonyl, N-methanesulfonyloxyethyl) C1-Minomethyl-D-ergoline is used as the starting compound. 3.1 g (60% of the theoretical yield) of the acidic maleic acid are obtained. 6-methyl-8- (N-methanesulfonyl, N-azidoethyl) -aminomethyl-ergoline. T. pl. 160-162 C, fci l - 38-, 94 ° Ls 0.5, 50% ethyl alcohol). EXAMPLE 6 Acidic maleic acid 1,6-dimethyl-8 - (((N-methanesulfonyl, L-azidoethyl) -aminomethyl7-ergoline. The process is carried out in the same manner as in Example 1, q by the difference that 4.6 g of 1,6-dimethyl-8- (N-methanesulfonyl, N-methanesulfonyl oxyethyl). aminomethylJ-ergoline are used as the starting compound. 3.08 g of the acidic maleic acid 1,6-dimethyl-8- (N -Methanesulfonyl, N-azidoethylaminomethyl-ergoline, mp: 155-157C, fotj | ,, 4 (c 0.5 50% ethyl alcohol). Example 7 Tartrate 2-bromo, 6- dimethyl-8- (N-methanesulfon l, N-azidoethyl) -aminomethyl3-ergoline. The process of d same as in example 2, with the difference that 4.16 g of 1,6-dimethyl-8- (N-m-tansulfonyl, N-azidoethyl) -aminomethyl ethyl ergoline is used as the starting compound and the resulting base is treated with methanol solution tartaric acid. As a result, 3.05 g (47% of the theoretical yield) of 2-bromo-1,6-dimethyl-8- (N-methanesulfonyl, N-azidoethyl) -aminomethyl-ergoline tartrate is obtained. mp. 213-215 ° C, -60.1 (c 0.1, pi. Ridin)., Example8. Preparation of the acidic maleic acid 6-, methyl-8- (N-methanesulfonyl, N methanesulfonyloxy-ethyl) aminomethyl} -ergol-8-ene used as the starting compound. 2.97 g of 6-methyl-8- (2-hydroxyethyl1 aminomethyl-ergol-8-ene is dissolved in 700 ml of anhydrous pyridine with stirring. The solution is cooled to and mixed with a solution of 2.29 g of methanesulfonic acid in 5 ml of acetonitrile. The reaction mixture is kept for one hour at the same temperature and then stirred for 3 hours at room temperature. The reaction is monitored by thin layer chromatography (adsorbent: silica gel on aluminum foil for thin layer chromatography 60/5553 from Merck, Germany, mobile phase : mixture x loroform, water and ethanol in a ratio of 100: 0.75: 20, developer: Van Urk's reagent.) At the end of the reaction, the mixture is poured into 200 ice water and shaken into l-: casting funnel with 500 ml of chloroform, pH the aqueous phase is adjusted with a 2% sodium carbonate solution to 7.5 and the mixture is shaken again in a separatory funnel, after which chloroform is separated. From the aqueous phase, extraction is carried out three times with 100 ml of chloroform. The organic layers were combined, dried over sodium sulfate, and evaporated in vacuo. The residue after evaporation is dissolved in a mixture of chloroform, water and ethanol in a ratio of 100: 0.3: 12 and introduced into a column filled with 60 g of silica gel (silica gel for column chromatography: Woelm 63-200). Elution is carried out with the above mixture of solvents. The purity of the substance obtained is determined by thin layer chromatography. Fractions with R 0.7 evaporated in vacuo. Salt is obtained from the residue after evaporation by treating it with an alcoholic solution of maleic acid. The result is 4.55 g (71% of theoretical yield) of acidic maleic acid 6-methyl-8- (N-methanesulfonyl, N-methanesulfonyloxyethyl) -aminomethyl J-ergol-8-ene, melting point of the resulting product 158-160 s, ffi- 33, 5 ° (with 0.5, 50% ethyl alcohol). Example 9. The preparation of the acidic maleic acid 6-methyl-6t (N-methanesulfonyl, N-methanesulfonyloxyethyl) aminomethyl 3-ergoline used as the starting material is carried out in the same way as in drimer 8, with the difference is that 3.0 g of 6-methyl-8- (2-hydroxyethyl) aminomethylJ-ergoline is used as the starting compound. As a result, 4.11 g (72% of the theoretical yield) of acid maleic acid b-methyl-B are obtained. - (N-methanesulfonyl, N-methanesulfonyloxyethyl) -aminomethyl-ergoline. T. pl. 138-140 ° C Cot3, 0 °, (with 0.5, 50% ethyl alcohol), Example 10, Preparation of the acidic maleic acid 1.6 dimethyl-8- (N- methanesulfonyl, N-methanesulfonyloxyethyl) -aminomethyl ergoline. The process is carried out in the same manner as in Example 8, with the difference that 3.15 g of 1, 6-dimethyl-8-C (2-hydroxyethyl) -gynomethyl ergoline is used as the starting compound. 3.7 g (64% of theoretical yield) of the acidic maleic acid of 1,6-dimethyl-8- (N-methanesulfonyl, N-methanesulfonyloxyethyl) -aminomethyl J-ergoline are obtained in the resultant. T. pl. 112-114 C, Cot 20 .. (with 0.5, 50% ethyl alcohol). The compounds of the formula D obtained according to the inventive method have an antagonistic svrotoninoretseporny, antidepressive and dopamine-receptor stimulating effect, as well as reduce blood pressure. The antagonistic serotonin-receptor effect of the compounds can be found in experiments carried out both in vitro and in vivo. When conducting in vitro tests on isolated smooth muscles, it was found that these compounds already at very low concentrations inhibited the contraction of smooth muscles caused by serotonin. When tested in vivo, they are severely inhibited by both parenteral and oral administration of serotonin-induced puffiness. This effect is particularly pronounced in the following compounds of general formula I: 1,6-dimethyl-8- (N-methanesulfonyl, N-azidoethyl) -aminomethyl-ergol-8-ene tartrate (Example 3); maleic acid 6-methyl-8- (N-methanesulfonyl, N-azidoethyl) -aminomethylZ-ergoline (Example 5); maleic acidic 1.6 dimethyl-8- (N-methanesulfonyl, N-azidoethyl) -: aminomethyl 3-ergoline (Example 6); 2-bromo-1,6-dimethyl8- (N-methanesulfonyl, N-azidoethyl) aminomethyl / -ergoline tartrate (Example 7). The efficacy of some of the above compounds is also equal to or greater than that of the acidic maleic acid (+) - butanolamide (2) -1-methyl-y-Lysergic acid (metizergid) used as a control compound. The acidic maleic acid D, 6-dimethyl-8- (N-methanesulfonyl, α-azidoethne) -aminomethyl - ergoline described in example 6 is more effective in oral administration than metisergide. Data on the effectiveness of the compounds are given in table. 1. The antiserotonic effect in vitro was determined on isolated uterus of rats according to the method I.A. Gaddum, L, A. Hairaned. In vivo experiments were performed on the plantar swelling of rats according to the method of I.L. Bonta. Some of the compounds of general formula I obtained by the proposed method have a marked antidepressant effect. Action used as a control compound 5- (3-dimethylaminopne O
    drank) -10,11-dihydro-5H-dibenzo-6, azepine (imipramine) does not exceed the effect of acidic maleic acid 6-methyl-8- (N-methanesulfonyl, N-aero ethyl) -aminomethyl-ergol- obtained in accordance with example 1 vein. These compounds are also active when administered orally. They are non-toxic. Their effectiveness depends on the dosage.
    Data on the activity of these compounds is given in table. 2,
    The antidepressant effect of the compounds was determined by using them as antasonists, hypothermia-causing reserpine by determining the body temperature and comparing it with the temperature of the control animal, ui is the temperature difference (V.M. Askew). Acute toxicity was determined on the map. Evaluation was performed 24 hours after drug administration (Lichfield, Wilcoxon).
    The acidic maleic acid 6-methyl-8- (N-methanesulfonyl, N-azidoethyl) -aminomethyl ergol-8-ene, described in example 1, has, in addition, a stimulatory effect of deputiaminreceptor. The activity of this compound in experiments in vitro is the same, and in experiments in vivo, higher than the activity of bromocriptine (2-bromo-o-ergocryptin). The pharmacodynamic effect of this compound is well manifested when administered orally.
    Data on its activity are given in table. 3
    The dopamine-receptor stimulating effect of the compounds was determined in vitrp on isolated, stimulated by an electric current, semen chi ducts by the muscle according to method I, .Hughes, H.W. Kosterlitz and P.M. Leslfe
    In in vivo experiments, rats were used as under-experimental animals. The antigonistic effect of the compounds on potentiated anesthesia caused by parenterally administered haloperidol in the amount of 5 mg / kg was determined. Anesthesia: Hexabarbital Na, 50 mg / kg intravenously.
    Some of the compounds obtained by the proposed method, with
    administering them in small doses to animals under anesthesia contribute to a decrease in blood pressure. The magnitude of the effect and the duration of action in the case of the compounds studied are higher than the corresponding values in the case of using dihydroergotemin as the control compound. A decrease in blood pressure with the use of the proposed compounds is accompanied by a decrease in heart rate (bradycardi). Connections inhibit negative reflexes in both central and peripheral structures. The mechanism of the effect of the compounds on blood pressure is somewhat different than in the case of alkaloids spores. The proposed compounds do not have an adrenalitic effect at all or exert it in a small
    0 degrees. Their action is manifested mainly in the vasomotor center. Compounds reduce blood pressure in animals with hypertension when administered orally. So,
    5 described in example 1 acidic maleic acid 6-methyl-8-, (N-methanesulfonyl, N-azidoethyl) -aminomethyl-ergol8-ene, when administered orally in the amount of 1.0-2.5 mg / kg awake rat, 14 patients with hypertension, reduced blood pressure., Its effect lasted for several hours. Compounds reduce blood pressure and during testing
    5 of them on cats.
    The results obtained in experiments on cats are given in table. four.
    Blood pressure was measured in cats under anesthesia (anesthesia was performed by administering
    0 30 mg / kg of pentothal-sodium salt of 5-ETHYL-5- (1-methylbutyl) -2-thiobarbituric acid) using a manometer (Statham P 23) injected into the left femoral artery and recorded 5 with the PO1 polygraph. Test compounds were injected into the npaBSTO femoral vein (MS Leod L.I).
    Thus, the proposed method allows to obtain new ergol-8-ene or ergodine derivatives of general formula Z, possessing valuable fa; makologicheskimi properties. Idisvrotonichesky Compound y) g / m as in vitro example 35-10- ° 51-10 61-10 75-10 Methieergid5-10 Aytidepressi Compound 4t, ° C In example 1 + 6,5 Imipramine +5,2 - - - - - - “---. ™“. "..." .- .. J ", Dopamine-receptor Semen-Outflow Duct Compound of Mouse, M (1), in vitro In Example 1 5 Bromocriptine: 5-10 ----. -. -., - dose, causing 50% Table oo effect, 50% inhibition of puffiness caused by serothoin, EOwt, mg / kg, in vivo subcutaneous 0.223.7 0.291.7 0.0420.47 0.32 , 0 0,260,64 Table2 effect of LDg, mg / kg parente-oral orally, 10 mg / kg 100 100 115 666 44 "." M ",. M" 4 ".. p.-. I t a b l and c a 3 stimulating effect On rats Haloperidol-antagoniam, mg / kg,% inhibition in yivo, subcutaneously, orally, 3.0 68.7 10.0 92.2 38.9 30.048.2 10.0 25, 9 30, 34.2 54.8. inhibition.
    eleven
    Connection example
    107280612
    .A6lita4
    Lower blood pressure
    time of hp m
    5 6 7
    Dihydroergotamine
    -50
    2
    -25
    2
    IfS
    -35
    -20
    1.5
    -50
    2
    -20
    1.5
    -40
    one
    -40
    1.5
    -50
    2
    -35
    2
    -25
    0.5
    权利要求:
    Claims (2)
    [1]
    The method of obtaining ergol-8-ene or ergoline derivatives of general form
    CH ~ S - yli CH 2 -CH-;
    K is hydrogen or methyl;
    ; Ρ · is hydrogen or bromine;
    - alkylsulfonyl,
    or their salts, which is different from the fact that the compound of the general formula
    CH 2 - ^ - CH2-CH2 -Kz '
    A to 2
    Where A I and K 2 have the indicated values;
    K hydrogen;
    K ^ -C ^ -C-- alkylsulfonyloxy group,
    subjected to interaction with alkali metal azide and, if necessary, brominated in position 2 with a booking agent and the obtained target products are isolated in free form
    or in the form of salts.
    one
    1072806
    [2]
    2
    类似技术:
    公开号 | 公开日 | 专利标题
    JP2002529467A|2002-09-10|Pyrazolopyrimidinone compounds effective in treating erectile dysfunction
    PT96143B|1997-05-28|PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED PYRROLIDINE DERIVATIVES ANTAGONISTS OF MUSCLE RECEPTORS
    US7071205B2|2006-07-04|5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
    SU1072806A3|1984-02-07|Process for preparing derivatives of ergol-8-ene or ergoline or their salts
    CS207666B2|1981-08-31|Method of making the 2-bromergosin and the additive salts thereof with the acid
    US8394824B2|2013-03-12|Quinuclidine compounds having quaternary ammonium group, its preparation method and use as blocking agents of acetylcholine
    SU1486062A3|1989-06-07|Method of producing n-alkylated dihydrolysergic acid
    JP6842474B2|2021-03-17|Steroid compounds, compositions containing the compounds and their use
    EP2618828A1|2013-07-31|Aprepitant l-proline composition and cocrystal
    EP0128479B1|1990-08-01|Pyrazole derivatives with an ergoline skeleton, a process for preparing them and pharmaceutical compositions containing these compounds
    KR950014866B1|1995-12-16|Ergolinyl heterocycles
    CN113272315A|2021-08-17|Steroid compounds and application thereof
    RU2101284C1|1998-01-10|Optically active carboxamide derivatives or their pharmacologically acceptable salts, pharmaceutical composition showing analgetic activity
    JP3251954B2|2002-01-28|Azabicyclo derivatives
    WO1988000192A1|1988-01-14|5-SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDIN-7-ONES
    KR20030002304A|2003-01-08|3-Phenyl-3,7-diazabicyclo[3.3.1]nonane compounds and process for their preparation and medicaments containing these compounds
    RU2058985C1|1996-04-27|Indole derivatives, process for preparation thereof and pharmaceutical composition based thereon for treating mental disorders
    CA1302405C|1992-06-02|Ergoline derivatives
    IL281996D0|2021-05-31|Solid forms of n-|-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide
    TW202146400A|2021-12-16|Phthalazinone compound and preparation method and pharmaceutical use thereof
    GB2030567A|1980-04-10|2-Bromo-9,10-dihydroergosine
    CN112358483A|2021-02-12|Novel benzodiazepine compound, preparation method and application thereof
    WO2021249534A1|2021-12-16|Phthalazinone compound, and preparation method therefor and medical use thereof
    Portlock et al.1975|Potential central nervous system antineoplastic agents. Amides of 6-cyano-6-norlysergic acid
    CS255875B1|1988-03-15|Process for preparing new derivatives of 2-halogennicergoline
    同族专利:
    公开号 | 公开日
    IL60548D0|1980-09-16|
    ES8106536A1|1981-10-16|
    SE436880B|1985-01-28|
    PH16358A|1983-09-08|
    ES493335A0|1981-07-16|
    CH644120A5|1984-07-13|
    FR2460949A1|1981-01-30|
    IT8023387D0|1980-07-11|
    DK160874C|1992-02-24|
    JPS5653677A|1981-05-13|
    CA1149801A|1983-07-12|
    ZA804198B|1981-07-29|
    DE3026271A1|1981-02-12|
    AU6034980A|1981-01-15|
    JPH0210834B2|1990-03-09|
    GB2055370B|1983-05-05|
    AU532293B2|1983-09-22|
    FR2460949B1|1983-01-21|
    SE8005126L|1981-01-13|
    SU1053752A3|1983-11-07|
    DK160874B|1991-04-29|
    DK300080A|1981-01-13|
    GB2055370A|1981-03-04|
    IT1149840B|1986-12-10|
    HU180467B|1983-03-28|
    US4299836A|1981-11-10|
    BE884171A|1981-01-05|
    IL60548A|1983-07-31|
    NL8004000A|1981-01-14|
    DE3026271C2|1991-07-25|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    NL278401A|1961-05-29|
    US3985752A|1974-12-06|1976-10-12|Eli Lilly And Company|6-Methyl-8- methylergolines|
    IT1064473B|1976-11-24|1985-02-18|Simes|8-BETA-AMINOMETHYLERGOLINE DERIVATIVES ON SULFAMOIL|GB2173189B|1985-02-21|1988-04-27|Maruko Pharmaceutical Co|Ergoline derivatives and salts thereof and pharmaceutical compositions thereof|
    DE3623438C2|1986-07-10|1998-04-09|Schering Ag|Ergolinyl urea derivatives labeled in the 2-position with radioactive iodine, process for their preparation and their use as diagnostics|
    US5242678A|1986-07-10|1993-09-07|Schering Aktiengesellschaft|BR-diagnostics for monoamine receptors|
    US20070243240A9|2000-08-24|2007-10-18|Fred Windt-Hanke|Transdermal therapeutic system|
    DE10043321B4|2000-08-24|2005-07-28|Neurobiotec Gmbh|Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and for lactation inhibition|
    DE10053397A1|2000-10-20|2002-05-02|Schering Ag|Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU79GO1452A|HU180467B|1979-07-12|1979-07-12|Process for producing new ergol-8-ene- and ergoline-sceleted compounds|
    [返回顶部]